The following unconjugated primary mouse antibodies were used at the indicated final concentrations: anti–CD207/Langerin (clone DCGM4, IgG1, 2 μg/mL; Beckman Coulter, Fullerton, CA), anti–CD1a (clone HI149, IgG1, 3.125 μg/mL; BD Biosciences, Franklin Lakes, NJ), anti–CD209/DC-SIGN (clone DCN46, IgG2b, 5 μg/mL; BD Biosciences), anti–CD208/DC-LAMP (clone 104.G4, IgG1, 2 μg/mL; Beckman Coulter), and anti–CD11c (clone B-ly6, IgG1, 10 μg/mL; BD Biosciences). As tertiary mouse antibodies, the following were used in an immunofluorescent double-staining technique: FITC-conjugated anti–HLA-DR (clone L243, IgG2a, 2.5 μg/mL; BD Biosciences), FITC-anti–CD45 (clone HI30, IgG1, 10 μg/mL; BD Biosciences), FITC-anti–CD1a (clone HI149, IgG1, 10 μg/mL; BD Biosciences), FITC-anti–CD11c (clone BU15, IgG1, 5 μg/mL; Serotec Ltd., Kidlington, Oxford, UK), FITC-anti–CD11b (clone ICRF44, IgG1, 5 μg/mL; Serotec), Alexa-488-conjugated anti–CD208/DC-LAMP (clone 104G4, IgG1, 50 μg/mL; Dendritics, Dardilly, France), FITC-anti–CD86 (clone 2331, IgG1, 4 μg/mL; BD Biosciences), and FITC-anti–CD80 (clone L307.4, IgG1, 8 μg/mL; BD Biosciences).